Gavilimomab is a monoclonal antibody that targets the CD4 receptor, which is primarily found on T lymphocytes. It is designed to modulate immune responses, particularly in the context of autoimmune diseases and certain types of cancer. As a therapeutic agent, Gavilimomab functions by binding to the CD4 molecule, potentially altering T cell activation and proliferation. This mechanism can help in regulating immune responses, making it a candidate for treating conditions where immune modulation is beneficial. The substance is characterized by its specificity for the CD4 receptor, which plays a crucial role in the immune system's function. Gavilimomab is typically administered via injection and is subject to rigorous clinical testing to evaluate its efficacy and safety profile. As with many monoclonal antibodies, potential side effects may include infusion reactions and increased susceptibility to infections due to immune system modulation. Overall, Gavilimomab represents a targeted approach in immunotherapy, reflecting the growing trend of utilizing biologics in modern medicine.

Gavilimomab

244096-20-6: Gavilimomab is a monoclonal antibody that targets the CD4 receptor, which is primarily found on T lymphocytes. It is designed to modulate immune responses, particularly in the context of autoimmune diseases and certain types of cancer. As a therapeutic agent, Gavilimomab functions by binding to the CD4 molecule, potentially altering T cell activation and proliferation. This mechanism can help in regulating immune responses, making it a candidate for treating conditions where immune modulation is beneficial. The substance is characterized by its specificity for the CD4 receptor, which plays a crucial role in the immune system's function. Gavilimomab is typically administered via injection and is subject to rigorous clinical testing to evaluate its efficacy and safety profile. As with many monoclonal antibodies, potential side effects may include infusion reactions and increased susceptibility to infections due to immune system modulation. Overall, Gavilimomab represents a targeted approach in immunotherapy, reflecting the growing trend of utilizing biologics in modern medicine.

<p>IgM murine monoclonal antibody targeting CD147.</p>

Gavilimomab(ABX-CBL) is a murine-derived IgM monoclonal antibody against CD147 antigen used in immunosuppressive treatments for glucocorticoid-resistant GVHD).

CAS 244096-20-6

Gavilimomab

Gavilimomab

Ref: 3D-CLA1091

Gavilimomab

Ref: TM-T82331